Charles Schwab’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-17,405
| Closed | -$38.5K | – | 3671 |
|
|
2023
Q2 | $38.5K | Hold |
17,405
| – | – | ﹤0.01% | 3458 |
|
|
2023
Q1 | $44.2K | Hold |
17,405
| – | – | ﹤0.01% | 3368 |
|
|
2022
Q4 | $32.5K | Hold |
17,405
| – | – | ﹤0.01% | 3443 |
|
|
2022
Q3 | $45K | Hold |
17,405
| – | – | ﹤0.01% | 3358 |
|
|
2022
Q2 | $34K | Sell |
17,405
-112,267
| -87% | -$245K | ﹤0.01% | 3454 |
|
|
2022
Q1 | $386K | Buy |
129,672
+7,019
| +6% | +$26.4K | ﹤0.01% | 3155 |
|
|
2021
Q4 | $551K | Buy |
122,653
+6,311
| +5% | +$29.9K | ﹤0.01% | 3116 |
|
|
2021
Q3 | $566K | Sell |
116,342
-186,328
| -62% | -$1.03M | ﹤0.01% | 3105 |
|
|
2021
Q2 | $2.06M | Buy |
302,670
+28,130
| +10% | +$227K | ﹤0.01% | 2708 |
|
|
2021
Q1 | $1.94M | Buy |
274,540
+3,062
| +1% | +$22K | ﹤0.01% | 2674 |
|
|
2020
Q4 | $1.7M | Buy |
271,478
+4,146
| +2% | +$24.4K | ﹤0.01% | 2640 |
|
|
2020
Q3 | $1.45M | Buy |
267,332
+5,678
| +2% | +$28.1K | ﹤0.01% | 2590 |
|
|
2020
Q2 | $1.37M | Buy |
261,654
+36,057
| +16% | +$160K | ﹤0.01% | 2546 |
|
|
2020
Q1 | $711K | Buy |
225,597
+24,569
| +12% | +$90.6K | ﹤0.01% | 2592 |
|
|
2019
Q4 | $811K | Buy |
201,028
+8,145
| +4% | +$28.3K | ﹤0.01% | 2667 |
|
|
2019
Q3 | $834K | Buy |
192,883
+26,435
| +16% | +$106K | ﹤0.01% | 2624 |
|
|
2019
Q2 | $665K | Buy |
166,448
+17,256
| +12% | +$82.1K | ﹤0.01% | 2706 |
|
|
2019
Q1 | $800K | Sell |
149,192
-8,343
| -5% | -$53.9K | ﹤0.01% | 2618 |
|
|
2018
Q4 | $809K | Sell |
157,535
-1,992
| -1% | -$15.1K | ﹤0.01% | 2602 |
|
|
2018
Q3 | $1.55M | Buy |
159,527
+19,397
| +14% | +$196K | ﹤0.01% | 2501 |
|
|
2018
Q2 | $1.43M | Buy |
140,130
+11,384
| +9% | +$129K | ﹤0.01% | 2475 |
|
|
2018
Q1 | $1.67M | Buy |
128,746
+36,380
| +39% | +$542K | ﹤0.01% | 2382 |
|
|
2017
Q4 | $1.65M | Buy |
92,366
+10,202
| +12% | +$213K | ﹤0.01% | 2362 |
|
|
2017
Q3 | $2.06M | Buy |
82,164
+45,556
| +124% | +$1.06M | ﹤0.01% | 2279 |
|
|
2017
Q2 | $883K | Buy |
36,608
+11,500
| +46% | +$254K | ﹤0.01% | 2500 |
|
|
2017
Q1 | $484K | Hold |
25,108
| – | – | ﹤0.01% | 2652 |
|
|
2016
Q4 | $387K | Hold |
25,108
| – | – | ﹤0.01% | 2749 |
|
|
2016
Q3 | $327K | Hold |
25,108
| – | – | ﹤0.01% | 2758 |
|
|
2016
Q2 | $350K | Buy |
25,108
+7,700
| +44% | +$113K | ﹤0.01% | 2728 |
|
|
2016
Q1 | $265K | Hold |
17,408
| – | – | ﹤0.01% | 2812 |
|
|
2015
Q4 | $331K | Hold |
17,408
| – | – | ﹤0.01% | 2825 |
|
|
2015
Q3 | $331K | Hold |
17,408
| – | – | ﹤0.01% | 2784 |
|
|
2015
Q2 | $449K | Buy |
+17,408
| New | +$494K | ﹤0.01% | 2713 |
|
Charles Schwab's PRTK Position: Q3 2023 in Review
Charles Schwab sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2023, closing a stake of 17,405 shares — an estimated $38.5K sold.
Charles Schwab first reported a position in PRTK in Q2 2015 and held it in 33 quarters. The position peaked at $2.06M in Q2 2021. 0 funds tracked by Wall St. Rank hold PRTK as of Q3 2023.
- Charles Schwab reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
- Charles Schwab sold 17,405 Paratek Pharmaceuticals, Inc. shares in Q3 2023, an estimated $38.5K.
- Charles Schwab first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2015 and held it in 33 quarters.
- Charles Schwab's Paratek Pharmaceuticals, Inc. position peaked at $2.06M in Q2 2021.
- 0 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2023.
Based on Charles Schwab's 13F filing for Q3 2023, filed 8 Nov 2023.